http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Cecchi, F. (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
An, E.,Ock, C.-Y.,Kim, T.-Y.,Lee, K.-H.,Han, S.-W.,Im, S.-A.,Kim, T.-Y.,Liao, W.-L.,Cecchi, F.,Blackler, A.,Thyparambil, S.,Kim, W. H.,Burrows, J.,Hembrough, T.,Catenacci, D. V. T.,Oh, D.-Y.,Bang, Y.- KLUWER ACADEMIC PUBLISHERS GROUP 2017 Annals of Oncology Vol. No.
<P><B>Abstract</B></P><P><B>Background</B></P><P>A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to accurately distinguish between GC patients who would and would not benefit from anti-HER2 therapies.</P><P><B>Patients and methods</B></P><P>GC patients (<I>n </I>=<I> </I>237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab. We applied mass spectrometry-based proteomic analysis to quantify HER2 protein expression in formalin-fixed tumor samples. Using HER2 expression as a continuous variable, we defined a predictive protein level cutoff to identify which patients would benefit from trastuzumab. We compared quantitated protein level with clinical outcome and HER2 status as determined by conventional HER2 diagnostics.</P><P><B>Results</B></P><P>Quantitative proteomics detected a 115-fold range of HER2 protein expression among patients diagnosed as HER2 positive by standard methods. A protein level of 1825 amol/µg was predicted to determine benefit from the addition of trastuzumab to chemotherapy. Trastuzumab treated patients with HER2 protein levels above this cutoff had twice the median overall survival (OS) of their counterparts below the cutoff (35.0 versus 17.5 months, <I>P </I>=<I> </I>0.011). Conversely, trastuzumab-treated patients with HER2 levels below the cutoff had outcomes similar to HER2-positive patients treated with chemotherapy. (Progression-free survival = 7.0 versus 6.5 months: <I>P </I>=<I> </I>0.504; OS = 17.5 versus 12.6 months: <I>P </I>=<I> </I>0.520). HER2 levels were not prognostic for response to chemotherapy.</P><P><B>Conclusions</B></P><P>Proteomic analysis of HER2 expression demonstrated a quantitative cutoff that improves selection of GC patients for trastuzumab as compared with current diagnostic methods.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
